/ /

  • linkedin
  • Increase Font
  • Sharebar

    Microstent approval makes big news in glaucoma world

    Clinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.

    Recent news: Santen to acquire InnFocus, developer of glaucoma drainage microshunt

    The approval was based on the COMPASS Study which included a two-year follow up for 500 mild-moderate glaucoma patients undergoing cataract surgery. The device reached its primary endpoint in that 73% of those with the implant had at least a 20% reduction in IOP, a statistically significant difference.

    The secondary effectiveness endpoint was also met in that 61% of patients in the device group achieved an IOP between 6 and 18 mm Hg at the 24-month postoperative examination without the use of medication. This was also a statistically significant difference.

    Related: Portable non-mydriatic device closes gap on tele-glaucoma screening

    "We are pleased by the FDA's decision to approve our CyPass Micro-Stent which establishes Alcon's presence in this emerging surgical category to treat mild to moderate glaucoma," said Mike Ball, chief executive officer, Alcon. "It will provide a less invasive means of lowering IOP than traditional glaucoma surgery, with the goal of lowering the patient's dependence on topical glaucoma medication. We are excited to offer this new option to surgeons and the patients they serve."

    The device is designed to work by enhancing the eye’s natural drainage pathways while only minimally disrupting the tissue.

    More MIGS: Allergan building presence in glaucoma with implant and MIGS device

    Good alternative

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results